Research programme: alpha-1-microglobulin - A1M PharmaAlternative Names: A1M-001; Alpha-1-microglobulin - A1M Pharma; α1-microglobulin - A1M Pharma
Latest Information Update: 10 Jul 2014
At a glance
- Originator A1M Pharma AB
- Class Recombinant proteins
- Mechanism of Action Free radical scavengers; Haemoglobin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Preeclampsia
Most Recent Events
- 08 Jul 2014 A1M 001 receives Orphan Drug status for Preeclampsia in European Union
- 08 Jul 2014 Preclinical trials in Preeclampsia in Sweden (IV)